VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02561 VISEN PHARMA-B

Closed Labour Day 04-30 16:08:11

26.700

+1.500

+5.95%

High26.920	Low25.200	Vol33.00K
Open25.200	D1 Closing25.200	Amplitude6.83%
Mkt Cap3.04B	Tradable Cap3.04B	Total Shares114.00M
T/O859.86K	T/O Rate0.03%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"VISEN PHARMA-B","latestPrice":26.7,"timestamp":1777536491340,"preClose":25.2,"halted":0,"volume":33000,"delay":0,"changeRate":0.05952380952380953,"floatShares":113999999,"shares":113999999,"eps":-2.7972890598679006,"marketStatus":"Closed Labour Day","change":1.5,"latestTime":"04-30 16:08:11","open":25.2,"high":26.92,"low":25.2,"amount":859862,"amplitude":0.068254,"askPrice":26.7,"askSize":600,"bidPrice":25.8,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.8121479383535353,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":25.2,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":4.024390219363474,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561/tweets","defaultTab":"tweets","newsList":[{"id":"1173430388","title":"宣泰医药-B 2025年首度实现收入并加速内分泌产品商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1173430388","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173430388?lang=en_us&edition=fundamental","pubTime":"2026-04-28 06:33","pubTimestamp":1777329183,"startTime":"0","endTime":"0","summary":"宣泰医药-B（VISEN PHARMA-B，股份代号：02561）于2025年实现自成立以来的首笔收入，全年录得人民币16.5万元销售额，成本为人民币14.6万元，毛利约为人民币1.9万元。同期净亏损扩大至人民币2.53亿元（2024年为人民币1.82亿元），主要源于持续的研发投入与管理费用增长。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药-B 2025年首度实现收入并加速内分泌产品商业化进程","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630345611","title":"Visen Pharmaceuticals announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630345611","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630345611?lang=en_us&edition=fundamental","pubTime":"2026-04-28 06:26","pubTimestamp":1777328787,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals will hold its annual general meeting in Shanghai, China on June 26, 2026.Shareholders will receive audited consolidated financial statements for fiscal 2025.Meeting will vote on re-election of one executive director, re-election of two independent non-executive directors, and authorization for board to set directors’ remuneration.Ernst & Young is up for reappointment as auditor, with board authorization to set auditor remuneration.Resolutions include mandates to repurchase up to 10% of issued shares, issue up to 20% of issued shares, and extend issuance mandate by shares repurchased under buyback mandate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to ge","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDLc3SCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629498012","title":"Visen Pharmaceuticals shareholders approve exclusive licence framework agreement at EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2629498012","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629498012?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:18","pubTimestamp":1776853092,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals held an extraordinary general meeting on April 22, 2026.Shareholders passed an ordinary resolution authorizing Visen to approve, confirm, and ratify an Exclusive Licence Framework Agreement signed March 26, 2026 with ELA Ascendis subsidiaries, including revised 2026 annual cap and future annual caps.An ordinary resolution was adopted to approve, confirm, and ratify a 1st Commercial Supply Framework Agreement signed March 26, 2026 between Visen HK and Ascendis Pharma Endocrinology Division, including revised 2026 annual cap and future annual cap.Investors also adopted an ordinary resolution to approve, confirm, and ratify a supplemental agreement signed March 26, 2026 to a 2nd Commercial Supply Framework Agreement between Visen HK and Ascendis Europe, including revised annual caps.Resolutions authorized directors to take actions and execute documents to implement these continuing connected transactions, without confirming completion of any transaction steps.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL7b2fP4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK","LU1201861249.SGD","BK4585","LU0130102774.USD","BK4135","LU0648001328.SGD","LU0980610538.SGD","LU1571399168.USD","LU1699723380.USD","LU0130517989.USD","BK4588","BK1161","LU0477156953.USD","BK4559","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196875265","title":"VISEN PHARMA-B Raises Connected-Transaction Caps to RMB270.61 Million for 2026-2028, Citing Commercialisation Needs","url":"https://stock-news.laohu8.com/highlight/detail?id=1196875265","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196875265?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:06","pubTimestamp":1774537618,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (VISEN PHARMA-B, 02561) has proposed sizeable increases to three sets of annual caps governing continuing connected transactions with Ascendis Pharma A/S subsidiaries,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121805431","title":"VISEN Pharma Schedules 22 April 2026 EGM to Ratify Exclusive Licence and Supply Agreements with Ascendis Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1121805431","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121805431?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:04","pubTimestamp":1774537490,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals has issued a proxy circular convening an extraordinary general meeting (EGM) for 10:00 a.m. on 22 April 2026 at Room 1701, 1788 Square, 1788 West Nanjing Road, Jing’an District,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100507931","title":"VISEN Pharmaceuticals Calls 22 Apr 2026 EGM to Ratify Licence and Supply Agreements with Ascendis Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1100507931","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100507931?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:03","pubTimestamp":1774537414,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (VISEN) has convened an extraordinary general meeting (EGM) for 10:00 a.m. on 22 Apr 2026 at Room 1701, 1788 Square, West Nanjing Road, Jing’an District, Shanghai. Shareholders...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163636636","title":"Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1163636636","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163636636?lang=en_us&edition=fundamental","pubTime":"2026-03-13 09:35","pubTimestamp":1773365728,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618585611","title":"BRIEF-Visen Pharmaceuticals Posts Loss For Year Of RMB253.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618585611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618585611?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:04","pubTimestamp":1773327843,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Posts Loss For Year Of RMB253.4 MillionMarch 12 (Reuters) - Visen Pharmaceuticals 2561.HK:LOSS FOR YEAR RMB253.4 MILLIONFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132192277","title":"VISEN PHARMA-B Reports Annual Results: R&D Expenses Reach 93.484 Million Yuan, Up 3.27% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1132192277","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132192277?lang=en_us&edition=fundamental","pubTime":"2026-03-12 22:58","pubTimestamp":1773327505,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) announced its annual results for the period ending December 31, 2025. During the period, the company recorded revenue of 16,500 yuan (Renminbi, same below) and other income of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618252130","title":"Visen Pharmaceuticals FY2025 loss widened 39% to RMB253.42 million, cash jumped more than doubled to RMB632.65 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618252130","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618252130?lang=en_us&edition=fundamental","pubTime":"2026-03-12 22:35","pubTimestamp":1773326147,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals reported FY 2025 revenue of RMB165,000 and a FY 2025 loss for the year of RMB253.42 million. FY 2025 research and development costs rose 5% to RMB93.48 million, which the company attributed to higher expenses related to technology transfer and localization. FY 2025 administrative expenses increased 33% to RMB115.14 million, driven by higher share-based payment expenses and increased professional service fees following the listing. FY 2025 selling and marketing expenses were RMB31.19 million, with the company saying the costs were incurred in the second half as it began substantive market development ahead of commercialization. Cash and cash equivalents at Dec. 31, 2025 were RMB632.65 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL3W48DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618130986","title":"Visen Pharmaceuticals - Loss for Year RMB253.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130986?lang=en_us&edition=fundamental","pubTime":"2026-03-12 22:35","pubTimestamp":1773326132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN4000U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193873570","title":"VISEN PHARMA-B (02561) Reports No Changes in Share Capital for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1193873570","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193873570?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:48","pubTimestamp":1772617693,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) released a monthly return for the period ending 28 February 2026, confirming that its authorized share capital stood at 500.00 million ordinary shares, each with a par value of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199340365","title":"VISEN Pharmaceuticals (2561) Schedules Board Meeting for 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1199340365","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199340365?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:37","pubTimestamp":1772444237,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (2561) announced that its board of directors will hold a meeting on 12 March 2026. Key topics include reviewing and approving the financial results for the year ended 31...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616112382","title":"Visen Pharmaceuticals Schedules Board Meeting to Approve Annual Results for Year Ended Dec. 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2616112382","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616112382?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:14","pubTimestamp":1772442861,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals  said its board will meet on Thursday, 12 March 2026 to consider and approve the group’s annual results for the year ended 31 December 2025 and their publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL30JyQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109419182","title":"VISEN Pharmaceuticals (02561) Reports January 2026 Monthly Return on Equity Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1109419182","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109419182?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:12","pubTimestamp":1770109967,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (02561) published a monthly return on equity movements for the period ended 31 January 2026. The authorised share capital remained unchanged at 500,000,000 ordinary shares, each...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155302875","title":"LongPei Growth Hormone Approved, Delivering a Boost to VISEN PHARMA-B (02561) Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=1155302875","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155302875?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:55","pubTimestamp":1769475317,"startTime":"0","endTime":"0","summary":"In recent years, the trend of \"long-acting replacement\" in the domestic growth hormone market has entered an accelerated phase: the market share of long-acting growth hormones has consistently...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606242161","title":"BRIEF-Visen Pharmaceuticals Says NMPA Approves Lonapegsomatropin (Skytrofa) For Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2606242161","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606242161?lang=en_us&edition=fundamental","pubTime":"2026-01-27 00:58","pubTimestamp":1769446698,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Says NMPA Approves Lonapegsomatropin (Skytrofa) For InjectionJan 26 (Reuters) - Visen Pharmaceuticals 2561.HK:NMPA APPROVES LONAPEGSOMATROPIN (SKYTROFA) FOR INJECTIONFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YP01P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606214350","title":"VISEN Pharmaceuticals' Growth Hormone Replacement Therapy Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2606214350","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606214350?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:10","pubTimestamp":1769425820,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals  said Chinese regulators approved the company's biologics license application for lonapegsomatropin, according to a Hong Kong bourse filing Monday.The medicine, which holds the Skytrofa trade name, is meant to be used as a once-weekly growth hormone replacement therapy in patients three years and older.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606190572","title":"Visen Pharmaceuticals - Nmpa Approves Lonapegsomatropin (Skytrofa) for Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2606190572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606190572?lang=en_us&edition=fundamental","pubTime":"2026-01-26 18:40","pubTimestamp":1769424047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YP01P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605284018","title":"VISEN Pharmaceuticals' (HKG:2561) largest shareholders are public companies who were rewarded as market cap surged HK$412m last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2605284018","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605284018?lang=en_us&edition=fundamental","pubTime":"2026-01-24 07:45","pubTimestamp":1769211908,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over VISEN Pharmaceuticals by public companies implies that the general public has...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/visen-pharmaceuticals-hkg2561-largest-shareholders-are-publi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/visen-pharmaceuticals-hkg2561-largest-shareholders-are-publi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.0723},{"period":"1month","weight":0.0349},{"period":"3month","weight":-0.2147},{"period":"6month","weight":-0.2977},{"period":"1year","weight":-0.3925},{"period":"ytd","weight":-0.186}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.","exchange":"SEHK","name":"VISEN PHARMA-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VISEN PHARMA-B(02561) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VISEN PHARMA-B,02561,VISEN PHARMA-B股票,VISEN PHARMA-B股票老虎,VISEN PHARMA-B股票老虎国际,VISEN PHARMA-B行情,VISEN PHARMA-B股票行情,VISEN PHARMA-B股价,VISEN PHARMA-B股市,VISEN PHARMA-B股票价格,VISEN PHARMA-B股票交易,VISEN PHARMA-B股票购买,VISEN PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VISEN PHARMA-B(02561) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}